What is the appropriate levosalbutamol (albuterol) syrup dosing for a child with asthma, including weight‑based dose, minimum dose, dosing intervals for acute attacks and maintenance, and age‑specific limits?

Levosalbutamol Syrup Dosing for Pediatric Asthma

Levosalbutamol (levalbuterol) syrup is not the standard formulation for asthma management in children—the FDA-approved formulation is nebulized inhalation solution, not oral syrup. The available evidence exclusively addresses nebulized levalbuterol and oral albuterol syrup, but not levosalbutamol syrup specifically.

FDA-Approved Levosalbutamol Dosing (Nebulized Solution Only)

Maintenance Therapy (Non-Acute)

For children 6-11 years:

• 0.31 mg three times daily via nebulization 1
• Maximum routine dose: 0.63 mg three times daily
• Administered every 6-8 hours

For adolescents ≥12 years:

• Starting dose: 0.63 mg three times daily via nebulization 1
• For more severe asthma or inadequate response: 1.25 mg three times daily
• Administered every 6-8 hours

Acute Exacerbations (Emergency/Hospital Setting)

Weight-based dosing for children:

• 0.075 mg/kg (minimum 1.25 mg) every 20 minutes for 3 doses 2, 3
• Then 0.075-0.15 mg/kg up to 5 mg every 1-4 hours as needed 2, 3

For adolescents/adults ≥12 years:

• 1.25-2.5 mg every 20 minutes for 3 doses 2, 3
• Then 1.25-5 mg every 1-4 hours as needed 2, 3

Critical Limitations

Levosalbutamol is NOT FDA-approved for children under 6 years of age 1. The drug label explicitly states indication only for patients "6 years of age and older."

No oral syrup formulation exists for levosalbutamol. All FDA-approved formulations are nebulized inhalation solutions in unit-dose vials of 0.31 mg, 0.63 mg, and 1.25 mg 1.

Alternative: Albuterol (Racemic) Syrup

If oral syrup administration is specifically required (though nebulized therapy is strongly preferred), racemic albuterol syrup has established pediatric dosing:

For children 6-14 years:

• 4 mg (2 mg/5 mL syrup) four times daily 4
• This dose demonstrated superior efficacy with acceptable side effects compared to 2 mg or 6 mg doses

For children 2-6 years:

• 1-2 mg every 8 hours 5, 6
• Start at 1 mg and increase to 2 mg if tolerated

Key Clinical Considerations

Nebulized formulations are vastly superior to oral syrup for acute asthma management. The guidelines universally recommend nebulized short-acting beta-agonists for exacerbations 2, 3, 2. Oral formulations have slower onset (peak effect at 2-4 hours vs. immediate with nebulized) and less targeted delivery 4.

Levosalbutamol provides equivalent efficacy to racemic albuterol at half the milligram dose 2, 3. This is because levosalbutamol contains only the active R-enantiomer, while racemic albuterol is 50% active R-enantiomer and 50% inactive S-enantiomer.

Monitor closely for adverse effects including tachycardia, tremor, and hypokalemia, particularly at higher doses 1. Patients receiving 1.25 mg doses require especially close monitoring for systemic effects.

If requesting oral syrup specifically: Clarify whether racemic albuterol syrup (which exists and has pediatric data) or nebulized levosalbutamol solution (FDA-approved) is intended, as levosalbutamol syrup is not a commercially available formulation.